Literature DB >> 26137409

An adjuvanted whole cell vaccine as post-remission immunotherapy for acute leukemia.

Robert Weinkove1, Lindsay R Ancelet1, John D Gibbins2, Ian F Hermans2.   

Abstract

Many acute leukemia patients treated with chemotherapy are at high risk of relapse without allogeneic stem cell transplantation, an immunotherapy that is limited by significant toxicity and donor availability. We propose that post-remission vaccination with a simple autologous whole cell vaccine adjuvanted with α-galactosylceramide may be effective to prevent relapse of acute leukemia.

Entities:  

Keywords:  NKT cell; acute leukemia; immunotherapy; α-galactosylceramide

Year:  2015        PMID： 26137409      PMCID： PMC4485719          DOI： 10.1080/2162402X.2014.995568

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy.

Authors:  Gerrit Weber; Ignazio Caruana; Rayne H Rouce; A John Barrett; Ulrike Gerdemann; Ann M Leen; Karen R Rabin; Catherine M Bollard
Journal:  Clin Cancer Res       Date:  2013-07-09       Impact factor: 12.531

Review 2.  Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

Authors:  Celalettin Ustun; Jeffrey S Miller; David H Munn; Daniel J Weisdorf; Bruce R Blazar
Journal:  Blood       Date:  2011-08-31       Impact factor: 22.113

3.  Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene.

Authors:  Hans B Ommen; Peter Hokland; Torsten Haferlach; Lotte Abildgaard; Tamara Alpermann; Claudia Haferlach; Wolfgang Kern; Susanne Schnittger
Journal:  Br J Haematol       Date:  2014-02-24       Impact factor: 6.998

4.  An autologous leukemia cell vaccine prevents murine acute leukemia relapse after cytarabine treatment.

Authors:  John D Gibbins; Lindsay R Ancelet; Robert Weinkove; Benjamin J Compton; Gavin F Painter; Troels R Petersen; Ian F Hermans
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

5.  Immunologic consequences of chemotherapy for acute myeloid leukemia.

Authors:  Anne Reilly; Leslie S Kersun; Eline Luning Prak; Jean Boyer; Kenyetta McDonald; Abbas F Jawad; Kathleen E Sullivan
Journal:  J Pediatr Hematol Oncol       Date:  2013-01       Impact factor: 1.289

6.  Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy.

Authors:  Robert Weinkove; Collin R Brooks; John M Carter; Ian F Hermans; Franca Ronchese
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

Review 7.  Acute myeloid leukemia: 2013 update on risk-stratification and management.

Authors:  Elihu H Estey
Journal:  Am J Hematol       Date:  2013-04       Impact factor: 10.047

Review 8.  Acute lymphoblastic leukaemia.

Authors:  Hiroto Inaba; Mel Greaves; Charles G Mullighan
Journal:  Lancet       Date:  2013-03-22       Impact factor: 79.321

Review 9.  Immunotherapeutic strategies for relapse control in acute myeloid leukemia.

Authors:  Anna Martner; Fredrik Bergh Thorén; Johan Aurelius; Kristoffer Hellstrand
Journal:  Blood Rev       Date:  2013-07-18       Impact factor: 8.250

Review 10.  Immunotherapy in acute myeloid leukemia.

Authors:  Mario Arpinati; Antonio Curti
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.